281 related articles for article (PubMed ID: 15943823)
21. A Comparison of the Hormonal Profile of Early Androgenetic Alopecia in Men With the Phenotypic Equivalent of Polycystic Ovarian Syndrome in Women.
Sanke S; Chander R; Jain A; Garg T; Yadav P
JAMA Dermatol; 2016 Sep; 152(9):986-91. PubMed ID: 27304785
[TBL] [Abstract][Full Text] [Related]
22. Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features.
Daan NM; Jaspers L; Koster MP; Broekmans FJ; de Rijke YB; Franco OH; Laven JS; Kavousi M; Fauser BC
Hum Reprod; 2015 Oct; 30(10):2376-86. PubMed ID: 26269538
[TBL] [Abstract][Full Text] [Related]
23. Effects of Metformin Treatment on Soluble Leptin Receptor Levels in Women with Polycystic Ovary Syndrome.
Liu RB; Liu Y; Lv LQ; Xiao W; Gong C; Yue JX
Curr Med Sci; 2019 Aug; 39(4):609-614. PubMed ID: 31346998
[TBL] [Abstract][Full Text] [Related]
24. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome.
Lerchbaum E; Schwetz V; Giuliani A; Pieber TR; Obermayer-Pietsch B
Fertil Steril; 2012 Nov; 98(5):1318-25.e1. PubMed ID: 22835450
[TBL] [Abstract][Full Text] [Related]
25. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
[TBL] [Abstract][Full Text] [Related]
26. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
27. Effect of oral micronized progesterone on androgen levels in women with polycystic ovary syndrome.
Woods KS; Reyna R; Azziz R
Fertil Steril; 2002 Jun; 77(6):1125-7. PubMed ID: 12057716
[TBL] [Abstract][Full Text] [Related]
28. Menstrual dysfunction in polycystic ovary syndrome: association with dynamic state insulin resistance rather than hyperandrogenism.
Ezeh U; Ezeh C; Pisarska MD; Azziz R
Fertil Steril; 2021 Jun; 115(6):1557-1568. PubMed ID: 33602559
[TBL] [Abstract][Full Text] [Related]
29. Measurement of selected androgens using liquid chromatography-tandem mass spectrometry in reproductive-age women with Type 1 diabetes.
Gunness A; Pazderska A; Ahmed M; McGowan A; Phelan N; Boran G; Taylor AE; O'Reilly MW; Arlt W; Moore K; Behan LA; Sherlock M; Gibney J
Hum Reprod; 2018 Sep; 33(9):1727-1734. PubMed ID: 30020477
[TBL] [Abstract][Full Text] [Related]
30. Association of CYP3A7*1C and serum dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome.
Goodarzi MO; Xu N; Azziz R
J Clin Endocrinol Metab; 2008 Jul; 93(7):2909-12. PubMed ID: 18445661
[TBL] [Abstract][Full Text] [Related]
31. Impact of glycemic variations on the regulation of androgen metabolism in obese women with polycystic ovary syndrome.
Ludwig AK; Goharian LG; Dietze T; Tauchert S; Rudolf S; Diedrich K; Schweiger U; Oltmanns KM
Fertil Steril; 2009 Jul; 92(1):271-6. PubMed ID: 18692843
[TBL] [Abstract][Full Text] [Related]
32. Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance.
Patlolla S; Vaikkakara S; Sachan A; Venkatanarasu A; Bachimanchi B; Bitla A; Settipalli S; Pathiputturu S; Sugali RN; Chiri S
Gynecol Endocrinol; 2018 Mar; 34(3):238-242. PubMed ID: 29068242
[TBL] [Abstract][Full Text] [Related]
33. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
Singh S; Akhtar N; Ahmad J
Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
[TBL] [Abstract][Full Text] [Related]
34. Increased Prevalence of Elevated DHEAS in PCOS Women with Non-Classic (B or C) Phenotypes: A Retrospective Analysis in Patients Aged 20 to 29 Years.
Carmina E; Longo RA
Cells; 2022 Oct; 11(20):. PubMed ID: 36291122
[TBL] [Abstract][Full Text] [Related]
35. The association of body mass index and biochemical hyperandrogenaemia in women with and without polycystic ovary syndrome.
Yasmin E; Balen AH; Barth JH
Eur J Obstet Gynecol Reprod Biol; 2013 Feb; 166(2):173-7. PubMed ID: 23102586
[TBL] [Abstract][Full Text] [Related]
36. Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters.
Sieminska L; Marek B; Kos-Kudla B; Niedziolka D; Kajdaniuk D; Nowak M; Glogowska-Szelag J
J Endocrinol Invest; 2004 Jun; 27(6):528-34. PubMed ID: 15717649
[TBL] [Abstract][Full Text] [Related]
37. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents.
Silfen ME; Denburg MR; Manibo AM; Lobo RA; Jaffe R; Ferin M; Levine LS; Oberfield SE
J Clin Endocrinol Metab; 2003 Oct; 88(10):4682-8. PubMed ID: 14557441
[TBL] [Abstract][Full Text] [Related]
38. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
39. Is it useful to measure DHEAS levels in PCOS?
Boucher H; Robin G; Ribière L; Martin C; Espiard S; Catteau-Jonard S
Ann Endocrinol (Paris); 2024 Apr; 85(2):95-99. PubMed ID: 38360397
[TBL] [Abstract][Full Text] [Related]
40. [Insulin resistance and serum concentrations of ovarian and adrenal androgen in obese women without additional disease and with policystic ovary syndrome].
Olszanecka-Glinianowicz M; Banaś M; Zahorska-Markiewicz B; Kuglin D; Mokrzycka J; Mentel A
Endokrynol Pol; 2005; 56(6):921-6. PubMed ID: 16821212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
